本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inozyme Pharma

4.00
0.0000
成交量:- -
成交額:583.41萬
市值:2.60億
市盈率:-2.38
高:4.00
開:4.00
低:4.00
收:4.00
52周最高:6.24
52周最低:0.7210
股本:6,491.57萬
流通股本:3,014.82萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.6822
每股收益(LYR):-1.6243
淨資產收益率:-141.69%
總資產收益率:-48.45%
市淨率:8.17
市盈率(LYR):-2.46

資料載入中...

2025/07/01

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

重要事件披露

Form 8-K - Current report
2025/06/21

重要事件披露

Form 8-K - Current report
2025/06/02

重要事件披露

Form 8-K - Current report
2025/05/16

重要事件披露

Form 8-K - Current report
2025/05/14

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/05/14

重要事件披露

Form 8-K - Current report
2025/03/11

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/03/10

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/03/10

重要事件披露

Form 8-K - Current report
2025/01/10

重要事件披露

Form 8-K - Current report
2024/12/10

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]